Promising results from the PRECESTO Phase 2a exploratory study: detailed analysis
CESTO II clinical study (phase 2b, ongoing) of drug candidate NFL-101 for withdrawal
smoking: communication of results in July 2024
Co-development of NFL-301, drug candidate to reduce alcohol consumption.
New formulation developed and patent application filed
Fundraising of €3 million in January 2023 and non-dilutive financing of up to €1.9 million in February 2023
(Bpifrance, France Recovery 2030 Plan)
Cash flow as of September 30, 2023 of €3.6 million. Cash horizon now secure until the end
2024
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), biopharmaceutical company which
develops botanical medicines for the treatment of dependencies and addictions, presents
its results for the first half of 2023 approved by the Board of Directors on October 5, 2023. At this
opportunity, NFL Biosciences looks back on its recent advances, in particular the promising results of
the PRECESTO exploratory study and confirms that the CESTO results communication strategy
It will allow full consideration of the study which will remain double-blind for up to 12 months.
followed, with results from this Phase 2b study expected in July 2024.